AIFF

Firefly is a pre-commercial neuroscience micro-cap ($19.1M cap) whose headline '+957% revenue growth' is a statistical mirage: the revenue history collapsed from $15.0M (FY2021) to $498K (FY2023) to $108K (FY2024) before 'rebounding' to just $1.14M in FY2025. Rebasing off a near-zero denominator, that growth rate says nothing about durability — this is effectively a startup that pivoted into the FDA-510(k)-cleared Evoke EEG/ERP platform, now in ~85 clinical sites, and is trying to build a subscription 'Firefly Flywheel.' The product and 56.5% gross margin are the one genuine positive, but at $1.14M of sales the business has not yet demonstrated it can scale.

The financials are those of a company fighting for survival, not compounding. FY2025 net loss was -$19.9M (worse than the prior year), operating loss -$8.86M, and operating cash flow -$8.19M. Accumulated deficit sits at -$112M against just $7.64M of equity. The provided cash figure ($682K) is stale as of FY2023, and the only current data point — $4.03M of current assets — is roughly half of one year's operating burn. That gap forces continued reliance on dilutive financing, exactly what the filing documents: warrant exercises, a March 2025 units offering at $3.00 with 36-month $4.00 warrants, prefunded warrants, and finder's warrants. Shares already grew +27.3% in a year, and the overhang guarantees more. Tellingly, those raises were priced at $3.00–$6.83 — the stock now trades at $1.29, far below where insiders and financiers put money in.